

Singular Health Group Ltd: SHG

## ASX Announcement

14<sup>th</sup> August 2023

### Notice pursuant to Section 708A(5)(e) of the Corporations Act 2001

Singular Health Group Ltd (ASX: SHG, "Singular Health", or the "Company") advises that it has completed the issue of 7,272,727 new fully paid ordinary shares in the Company ("Shares") at \$0.055 per share to raise \$400,000. The Company has also completed the issue of 3,636,363 unlisted free attaching options exercisable \$0.10, expiry 3 years from date of issue ("Options"). The Shares and Options were issued in respect of Tranche 3 of the placement previously announced to the ASX on 10th May 2023 and as approved by shareholders at the Company's recent EGM held on 16 June 2023.

Please refer to the accompanying Appendix 2A and Appendix 3G which contains further details in respect of the allotment of the Shares and Options.

### Notice pursuant to Section 708A(5)(e) of the Corporations Act 2001

The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) ("**Corporations Act**") that:

1. the Company issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
2. the Company is providing this notice under section 708A(5)(e) of the Corporations Act;
3. as at the date of this notice, the Company has complied with:
  - a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - b. sections 674 and 674A of the Corporations Act; and
4. as at the date of this notice, there is no "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by the Company.

Authorised for ASX release by the Company Secretary.

Ends

For further information contact

Investors	Corporate
James Hill +61 413 825 646 jhill@singular.health	Steven Wood Company Secretary support@singular.health

**About Singular Health:**

Singular Health Group Limited (ASX:SHG) is a medical technology company utilising advanced technologies to develop patient-specific solutions.

Singular Health's 3Dicom software solutions empower patients and practitioners to better visualise, communicate, and understand medical imaging data. 3Dicom MD® is cleared for diagnostic use in the United States

Singular 3DP, a wholly owned subsidiary of Singular Health, uses advanced 3D printing and post-processing to manufacture TGA-approved patient-specific medical devices and offers contract manufacturing & post-processing services to other medical device manufacturers.

To learn more, visit: <https://www.singular.health> and <https://investors.singular.health/>